PDF(Pubmed)
Abstract：
Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies. Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %. Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to those who received CAR-T therapy alone. In conclusion, the results of this clinical trial provide compelling evidence for the safety and efficacy of using CAR-T therapy as a bridging strategy to allo-HSCT in patients with R/R B-ALL.
摘要：
嵌合抗原受体（CAR）-T细胞疗法已被证实可改善难治性患者或复发性B细胞急性淋巴细胞白血病（R/RB-ALL）的缓解率。然而,CAR-T治疗后接受异基因造血干细胞移植(allo-HSCT)的额外益处仍是一个有争议的话题.在这项研究中，我们调查了CD19CAR-T桥接与allo-HSCT在R/RB-ALL患者中的效率和长期结果。共有42名患者被纳入队列研究。我们的发现显示，接受CAR-T和HSCT的患者的1年总生存率（OS）为70％，1年无白血病生存率（LFS）为95％。此外，与接受单独CAR-T治疗的患者相比,接受这种联合治疗的患者具有更高的OS和LFS率.总之,这项临床试验的结果为在R/RB-ALL患者中使用CAR-T疗法作为allo-HSCT的桥接策略的安全性和有效性提供了令人信服的证据.
